Hetronifly 100 mg Injection USA | Bulk Oncology Exporter from India

Hetronifly 100 mg Injection: A New Standard in First-Line Immunotherapy for ES-SCLC

Are you looking for a trusted Hetronifly 100 mg injection exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a global leader in the distribution and bulk supply of advanced oncology biologics. We maintain a robust, cold-chain-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving immunotherapies reach patients and clinics with pharmaceutical-grade integrity.

Detailed Product Overview: What is Hetronifly 100 mg?

Hetronifly 100 mg Injection is a cutting-edge cancer immunotherapy containing the active substance, Serplulimab. It is a humanized monoclonal antibody designed as a programmed cell death-1 (PD-1) receptor inhibitor.

Developed by Shanghai Henlius Biotech and marketed globally by Accord Healthcare (an Intas Pharmaceuticals subsidiary), Hetronifly is the world’s first anti-PD-1 monoclonal antibody approved specifically for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). For international B2B procurement, Hetronifly provides a high-potency, clinically superior alternative to traditional treatments.

Primary Therapeutic Indications

Hetronifly 100 mg is indicated for the management of the following: 

1. Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Used in combination with carboplatin and etoposide as a first-line therapy for adult patients with previously untreated ES-SCLC.

2. Advanced Solid Tumors (MSI-H/dMMR): Indicated for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors that have progressed after prior therapy.

3. Squamous Non-Small Cell Lung Cancer (sqNSCLC): Approved in various regions for squamous cell lung cancer protocols.

Mechanism of Action: How Hetronifly Works

Hetronifly (Serplulimab) acts as an immune checkpoint inhibitor to reactivate the body's natural defenses against tumors.

• PD-1 Receptor Blockade: Serplulimab binds specifically to the PD-1 receptors on T-cells.

• Preventing Immune "Switch-Off": Cancer cells often produce proteins (PD-L1 and PD-L2) that bind to PD-1 to effectively "switch off" the immune response. Hetronifly blocks this interaction.

• Restoring Anti-Tumor Activity: By keeping the PD-1 receptor free, the medication restores the ability of T-cells to recognize, attack, and destroy cancer cells throughout the body.

Administration and Safety Guidelines

• Dosage: Administered via intravenous (IV) infusion. The standard regimen for ES-SCLC involves a dose based on body weight (typically 4.5 mg/kg) or a flat dose, usually given every three weeks.

• Infusion Duration: The first infusion typically takes 60 minutes. If well-tolerated, subsequent infusions may be shortened to 30 minutes.

• Cold-Chain Storage: Must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake.

• Key Precautions:

  • Immune-Mediated Adverse Reactions: Monitor for pneumonitis, colitis, hepatitis, and endocrinopathies (thyroid dysfunction).

  • Infusion Reactions: Patients should be observed for fever, chills, or rash during the procedure.

  • Monitoring: Regular liver, kidney, and thyroid function tests are mandatory throughout treatment.

Why Source Hetronifly from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Intas/Accord supplies, ensuring 100% product authenticity and competitive bulk pricing.

• Global Cold-Chain Mastery: Validated temperature-controlled packaging to maintain the stability of Serplulimab during transit to the USA, the UK, Australia, and South Africa.

• Regulatory Expertise: Extensive experience navigating import regulations and customs for specialty oncology medications across four continents.

• B2B Supply Stability: We specialize in fulfilling large-scale orders for hospitals, oncology specialty clinics, and regional healthcare distributors.